WuXi Biologics (Cayman) Inc (HKSE:02269) Share Price

Company Profile

Business description
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
Contact
No. 108, Meiliang Road
Mashan Binhu District
Wuxi214092
CHN
https://www.wuxibiologics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13,252

Recommended

With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.

Dan Romanoff, CPA | 08 May 2026

Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.

Seth Goldstein, CFA | 08 May 2026

With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.

Jacob Robbins | 08 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,980.50	31.60	-0.35%
CAC 40	8,112.57	89.51	-1.09%
DAX 40	24,338.63	324.98	-1.32%
Dow JONES (US)	49,609.16	12.19	0.02%
FTSE 100	10,233.07	43.88	-0.43%
HKSE	26,393.71	232.57	-0.87%
NASDAQ	26,247.08	440.88	1.71%
Nikkei 225	62,713.65	120.19	-0.19%
NZX 50 Index	13,175.13	95.48	-0.72%
S&P 500	7,398.93	61.82	0.84%
S&P/ASX 200	8,744.40	36.40	-0.41%
SSE Composite Index	4,179.95	0.14	-0.00%